Dr. Hutchinson is the principal investigator overseeing the research activities of TACL, Therapeutic Advances in Childhood Leukemia at the University of Michigan; this research group supports clinical trials for the treatment of many pediatric malignancies. He also has clinical research interests in the use of anti-tumor vaccines to treat patients with resistant sarcoma and in the use of radiolabelled MIBG to treat patients with neuroblastoma. Several clinical protocols are available in these areas. Dr. Hutchinson is a participant in the Childhood Cancer Survivor Study, an organization funded by the National Institutes of Health to investigate long-term outcomes of children and adolescents surviving their cancers. He also collaborates in the therapeutic advances for childhood Leukemia Consortium, a research group evaluating new therapies for acute leukemia.